Quarterly Updates
Fund performance and portfolio highlights
Continued Portfolio Momentum
Q1 2025 | Published April 15, 2025
Dear Partners,
The portfolio delivered strong performance in Q1 2025, driven by continued commercial traction across our MedTech and HealthTech holdings. Net NAV increased 4.2% quarter-over-quarter.
Portfolio Highlights
Caresyntax completed Series D financing at a significant step-up to our entry valuation
Avive Solutions received expanded FDA clearance for next-generation AED platform
Kardium achieved record quarterly procedure volumes across US hospital partners
Huma expanded enterprise contracts with three new health system partnerships
New Investments
One new platform investment completed in Q1 (details in portfolio section)
Outlook
We remain constructive on the healthcare growth equity opportunity set. Our pipeline is active with several late-stage opportunities under evaluation.